|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An approximately 20-fold amplification of the unmutated K-ras gene was observed in a tumor that proved to be a solitary lung metastasis of a rectal carcinoma.
|
3041218 |
1987 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women.
|
10884918 |
2000 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to evaluate whether the presence of c-K-ras gene mutations is a useful tumor-response marker in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.
|
11129419 |
2000 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The hot mutation areas of p53 gene (in exons 5-8) and K-ras gene (in codon 5/12 and 13) were detected with polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP), and overexpression of p53 protein was detected with immunohistochemistry (IHC) in the 97 specimens of rectal cancer.
|
15534934 |
2004 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Alcohol and the risk of colon and rectal cancer with mutations in the K-ras gene.
|
16905440 |
2006 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis revealed that MSI-H (HRR 2.47, 95% CI 1.13-5.40) and KRAS2 mutations (HRR 1.37, 95% CI 1.04-1.81) were associated with a significantly higher risk of dying of rectal cancer.
|
19669908 |
2009 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, data specifically for locally advanced rectal cancers are scarce, and the frequency of KRAS mutations in codons 61 and 146 remains to be established.
|
19913317 |
2010 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRAS testing on colo-rectal carcinoma cytological imprints.
|
20607679 |
2011 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We then used this comprehensive description of the rectal cancer transcriptome as the baseline for identifying KRAS-dependent alterations.
|
20725992 |
2010 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data show that EGFR GCN and KRAS status are not prognostic factors in LARC treated with preoperative chemoradiation.
|
20842128 |
2010 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The predictive and prognostic value of the KRAS and BRAF point mutations as well as PTEN expression in patients with locally advanced rectal cancer (LARC) treated with cetuximab-based neoadjuvant chemoradiotherapy is unknown.
|
20947270 |
2011 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the Cox regression analysis, only when colon and rectal cancer were analysed separately, KRAS mutation was a negative predictor for OS in patients with rectal cancer and DFS in those with stage II colon cancer.
|
20959826 |
2010 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study suggests that pretreatment intratumoral EGFR and VEGF mRNA expression levels as well as KRAS mutation status are predictive markers of pathologic response to neoadjuvant cetuximab-based chemoradiation in locally advanced rectal cancer.
|
21558395 |
2011 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study suggested EGF A+61G polymorphism to be a predictive marker for pCR, independent of KRAS mutation status, to cetuximab-based neoadjuvant chemoradiation of patients with locally advanced rectal cancer.
|
21673069 |
2011 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The possibility that statin use may be associated with lower risk of rectal cancer or KRAS wild-type colorectal cancer requires further confirmation.
|
21680706 |
2011 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The identified MSI and KRAS mutational prevalences parallel those reported in the rectal cancer literature.
|
21836482 |
2011 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to explore the relationships of KRAS and BRAF mutation status with p-AKT and p-ERK and outcomes in RC.
|
21910869 |
2011 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
|
22672749 |
2013 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to establish a correlation between specific KRAS mutations and rectal cancer response to CRT and to investigate if the correlation was related to a different association between KRAS and TP53 mutations.
|
23456389 |
2013 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study has identified a subgroup of more aggressive rectal cancers that may arise through the KRAS-p16 pathway.
|
24259266 |
2014 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study is the first to compare different SMIs in combination with IR for the treatment of K-RAS mutant rectal cancer, and our findings suggest that Chk1/2 inhibitors should be evaluated in new clinical trials for LARC.
|
24349411 |
2013 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The accuracy of SUVmax for predicting mutated KRAS was higher in patients with colon or sigmoid colon cancers, whereas it was TW40% in those with rectal cancers.
|
24978328 |
2014 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using a database of 735 colon and rectal cancers in the Nurse's Health Study and the Health Professionals Follow-up Study, we examined the relationship of tumor SMO expression (assessed by immunohistochemistry) to prognosis, and to clinical, pathological, and tumor molecular features, including mutations of KRAS, BRAF, and PIK3CA, microsatellite instability, CpG island methylator phenotype (CIMP), LINE-1 methylation, and expression of phosphorylated AKT and CTNNB1.
|
25023548 |
2014 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this prospective study was to analyse the association between infection of a tumour by HCMV and EBV and clinical, histological, metabolic ((18)F-FDG uptake), volumetric (from CT) and molecular (KRAS status) features and long-term outcomes in a homogeneously treated group of patients with locally advanced rectal cancer.
|
25269837 |
2015 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer.
|
25304881 |
2015 |